Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

PsoProtect Registry Data Update

psoprotect_update_615

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,652 cases. Below is a summary of the data collected or view the full report on the PsoProtect website.

Average age: 48 years
Phenotype of psoriasis: 1,605 plaque psoriasis, 47 pustular psoriasis
Average BMI: 27.7 kg/m2
Average number of days of symptoms from COVID-19: 10 days

Cases reported by country of assessment (≥20 cases):

PsoProtect 6-15-22_country

Severity of psoriasis at time of onset of COVID-19 (PGA):

PsoProtect 6-15-22_severity

Hospitalization required due to COVID-19:

PsoProtect 6-15-22_hospital

In addition to demographics, PsoProtect collects the following types of de-identified data:

  • Psoriasis disease characteristics, comorbidities and systemic treatment for psoriasis at onset of COVID-19
  • COVID-19 characteristics and disease course
  • COVID-19 outcome

We encourage clinicians to continue reporting cases of COVID-19 (suspected or confirmed) in psoriasis via the simple online PsoProtect case report form.

*Data are preliminary and include a limited number of cases and should not be used to inform clinical decision making

Categories

Recent Posts

IPC Welcomes New Councilors Dr. Steven Fakharzadeh and Dr. Rodrigo Garcia Salinas

A New Genetic Clue in Psoriasis: What the ADAR1 Discovery Means

Skin-Derived Myeloid Precursors and Joint-Resident Fibroblasts Spread Psoriatic Disease from Skin to Joints

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

Videos Now Available from the IPC Symposium at SID Chicago

Did you miss the IPC symposium at the 83rd Society for Investigative Dermatology (SID) Annual Meeting? Select session videos are now available. The Arc of Disease Control in Psoriasis: Early Interception – Deep Pathway Blockade – Treatment Failure covered early intervention strategies, treatment selection, immune pathway targeting, PsA prevention, clinical escape, and real-world cases that inform long-term psoriasis care.

WATCH NOW

Wednesday, June 17, 2026

Take Ten: Mio Nakamura – Psoriasis and Mental Health

Depression affects approximately 20% of patients with psoriasis, five times the rate seen in the general population. IPC Jr. Councilor Mio Nakamura, MD, MS, FAAD, walks through the bidirectional relationship between psoriasis and depression, the shared inflammatory pathways driving both conditions, and practical guidance on screening and incorporating multidisciplinary mental health support into psoriasis management.

WATCH NOW

Thursday, June 11, 2026